Daily FNArena News - Australia

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest

Previous Stories

FNArena Corporate Results Monitor

Aug 10 2018

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.


FNArena Corporate Results Monitor

Aug 09 2018

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.


ComBank Outlook Warrants Caution

Aug 09 2018

The outlook for Commonwealth Bank warrants caution, brokers suggest, despite a strong core retail banking franchise.


IOOF Confident Despite Industry Scrutiny

Aug 09 2018

While IOOF is confident its platform and advice segments can withstand regulatory scrutiny, several brokers are more cautious about dismissing the industry impact from the ongoing Royal Commission.


Slowing Growth A Challenge For Transurban

Aug 08 2018

The challenge brokers foresee for Transurban is generating growth off an increasingly large and complex base.


FNArena Corporate Results Monitor

Aug 08 2018

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.


Lend Lease A Winner In Global Development

Aug 08 2018

The next phase of growth is being revealed at Lend Lease as increasing amounts of capital are being allocated to development.


Seek Hunting Market Dominance

Aug 07 2018

Seek has disappointed those on the lookout for extra profits in FY19 as it ramps up expenditure to capture market share.


FNArena Corporate Results Monitor

Aug 06 2018

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments.


Expanded Product Offering Underpins ResMed

Aug 06 2018

Robust US economic conditions in FY19 should support ResMed amid stable pricing and an expanding product pipeline.



Analyse The Market From A Different Angle